Aytu BioPharma, Inc. (AYTU) financial statements (2022 and earlier)

Company profile

Business Address 373 INVERNESS PARKWAY
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,277 48,08211,0447,013802
Cash and cash equivalents35,277 48,08211,0447,013802
Restricted cash and investments  25225010075
Receivables22,989 5,1761,741579528
Inventory, net of allowances, customer advances and progress billings16,558 9,9991,4401,3391,312
Inventory16,558 9,9991,4401,3391,312
Prepaid expense11,298     
Other current assets1,418 5,742   
Other undisclosed current assets  5,715958440311
Total current assets:87,540 74,96615,4339,4703,029
Noncurrent Assets
Finance lease, right-of-use asset292  
Operating lease, right-of-use asset3,845 634
Property, plant and equipment  259204219647
Intangible assets, net (including goodwill)127,688 49,277221246751
Goodwill46,349 28,090  238
Intangible assets, net (excluding goodwill)81,339 21,187221246513
Deposits noncurrent assets  33253
Other noncurrent assets457 16,58718,86211,1209,231
Other undisclosed noncurrent assets4,002 11,081  1,337
Total noncurrent assets:136,284 77,87119,28911,59011,970
TOTAL ASSETS:223,824 152,83634,72121,06014,999
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,726 19,8493,4452,3063,003
Accounts payable  11,8252,2972,1202,220
Accrued liabilities50,685 7,8501,148186783
Employee-related liabilities5,041     
Taxes payable  175   
Deferred revenue200 339
Debt16,343 982   
Deferred rent credit    1
Business combination, contingent consideration, liability1,206 7131,078547261
Other liabilities  840   
Other undisclosed current liabilities27,096 5,583849541346
Total current liabilities:100,571 28,3075,3733,3953,610
Noncurrent Liabilities
Long-term debt and lease obligation129 11,897   
Long-term debt, excluding current maturities  11,171   
Finance lease, liability129  
Operating lease, liability2,716 725
Other undisclosed long-term debt and lease obligation(2,716)     
Liabilities, other than long-term debt8,857 17,61822,2614,2417,388
Deferred revenue and credits 1
Other liabilities560 4,732   
Business combination, contingent consideration, liability8,297 12,87422,2484,1477,387
Derivative instruments and hedges, liabilities  111394 
Other undisclosed noncurrent liabilities8,731     
Total noncurrent liabilities:17,717 29,51422,2614,2417,388
Total liabilities:118,288 57,82127,6347,63610,999
Stockholders' equity
Stockholders' equity attributable to parent105,536 95,0157,08813,4254,000
Preferred stock   0  
Common stock3 13200
Additional paid in capital323,231 215,013113,47592,68273,069
Accumulated deficit(217,698) (120,010)(106,390)(79,258)(69,070)
Total stockholders' equity:105,536 95,0157,08813,4254,000
TOTAL LIABILITIES AND EQUITY:223,824 152,83634,72121,06014,999

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
Revenues26,354 27,6327,3203,6603,222
Cost of revenue(33,199) (7,553)(2,202)(2,051)(1,417)
Gross profit:35,305 20,0795,1181,6101,804
Operating expenses(107,410) (48,763)(24,167)(23,360)(23,347)
Other undisclosed operating income9,040 7,5532,2022,0511,417
Operating loss:(63,065) (21,131)(16,847)(19,700)(20,125)
Nonoperating income (expense)4,818 7,510(10,285)9,512(2,383)
Other nonoperating income (expense)(20)  816,278 
Interest and debt expense(8) (316)(536)(749)(2,534)
Other undisclosed loss from continuing operations before equity method investments, income taxes(1,569)     
Loss from continuing operations before equity method investments, income taxes:(59,825) (13,936)(27,667)(10,937)(25,043)
Other undisclosed income from continuing operations before income taxes1,577     
Loss from continuing operations before income taxes:(58,248) (13,936)(27,667)(10,937)(25,043)
Income tax benefit110     
Other undisclosed loss from continuing operations(259)     
Net loss:(58,397) (13,936)(27,667)(10,937)(25,043)
Other undisclosed net income attributable to parent  3165367492,534
Net loss available to common stockholders, diluted:(58,397) (13,621)(27,132)(10,188)(22,508)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
Net loss:(58,397) (13,936)(27,667)(10,937)(25,043)
Comprehensive loss, net of tax, attributable to parent:(58,397) (13,936)(27,667)(10,937)(25,043)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: